Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,152,078
  • Shares Outstanding, K 181,530
  • Annual Sales, $ 1,704 M
  • Annual Income, $ -23,850 K
  • 60-Month Beta 0.69
  • Price/Sales 8.21
  • Price/Cash Flow 120.91
  • Price/Book 3.40
Trade BMRN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.06
  • Number of Estimates 8
  • High Estimate 0.06
  • Low Estimate -0.20
  • Prior Year 0.09
  • Growth Rate Est. (year over year) -166.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
71.65 +9.07%
on 11/03/20
79.42 -1.60%
on 11/04/20
+0.62 (+0.80%)
since 10/23/20
3-Month
71.35 +9.53%
on 09/11/20
80.94 -3.45%
on 09/22/20
+3.75 (+5.04%)
since 08/25/20
52-Week
68.25 +14.51%
on 03/23/20
131.95 -40.77%
on 07/21/20
-1.72 (-2.15%)
since 11/25/19

Most Recent Stories

More News
Downtrend Call Working As Biomarin Pharmac Stock Falls 35.4% (BMRN)

SmarTrend identified a Downtrend for Biomarin Pharmac (NASDAQ:BMRN) on July 30th, 2020 at $120.70. In approximately 4 months, Biomarin Pharmac has returned 35.38% as of today's recent price of $77.99....

BMRN : 78.15 (+0.24%)
SHAREHOLDER ALERT: BMRN RCL LOOP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / November 24, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered...

BMRN : 78.15 (+0.24%)
RCL : 80.08 (-1.90%)
LOOP : 8.61 (+1.89%)
Pfizer (PFE) Begins Phase III Study on Hemophilia Candidate

Pfizer (PFE) doses the first participant in the late-stage BASIS study, currently investigating marstacimab to address severe hemophilia A or B with or without inhibitors.

PFE : 36.53 (-0.19%)
BMRN : 78.15 (+0.24%)
SGMO : 9.77 (-2.01%)
QURE : 46.50 (+0.11%)
Lawsuits Filed Against BMRN, BIIB and YY - Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / November 24, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies...

BMRN : 78.15 (+0.24%)
BIIB : 241.75 (-0.31%)
YY : 90.90 (+2.45%)
BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ: BMRN)...

BMRN : 78.15 (+0.24%)
FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Reminds BioMarin Pharmaceutical Inc. Investors of Important November 24 Deadline in Securities Class Action - BMRN

New York, New York--(Newsfile Corp. - November 24, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between...

BMRN : 78.15 (+0.24%)
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of BMRN, CACC and TRQ

NEW YORK, NY / ACCESSWIRE / November 24, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies....

BMRN : 78.15 (+0.24%)
CACC : 298.34 (-3.05%)
TRQ : 9.66 (-9.80%)
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ:...

BMRN : 78.15 (+0.24%)
LAWSUITS FILED AGAINST BMRN, HPQ and YY - Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / November 23, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies...

BMRN : 78.15 (+0.24%)
HPQ : 22.25 (+2.30%)
YY : 90.90 (+2.45%)
BMRN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 24, 2020 in the Class Action Filed on Behalf of BioMarin Pharmaceutical Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - November 23, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)...

BMRN : 78.15 (+0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment...

See More

Key Turning Points

2nd Resistance Point 80.20
1st Resistance Point 79.17
Last Price 78.15
1st Support Level 77.33
2nd Support Level 76.52

See More

52-Week High 131.95
Fibonacci 61.8% 107.61
Fibonacci 50% 100.10
Fibonacci 38.2% 92.58
Last Price 78.15
52-Week Low 68.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar